Structure Therapeutics Inc. Research and Development Expense
Structure Therapeutics Inc. (GPCR) reported Research and Development Expense of $100.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Structure Therapeutics Inc. research and development expense for the quarter ending 2026-06-30 was $100.06M, a 82.89% increase year-over-year.
- Structure Therapeutics Inc. research and development expense for the quarter ending 2026-03-31 was $66.51M, a 55.15% increase year-over-year.
- Structure Therapeutics Inc. research and development expense for the quarter ending 2025-12-31 was $68.69M, a 105.12% increase year-over-year.
- Structure Therapeutics Inc. research and development expense for the quarter ending 2025-09-30 was $58.99M, a 80.96% increase year-over-year.
- Structure Therapeutics Inc. research and development expense for fiscal 2025 was $225.25M, a 107.01% increase from fiscal 2024.
- Structure Therapeutics Inc. research and development expense for fiscal 2024 was $108.81M, a 55.22% increase from fiscal 2023.
- Structure Therapeutics Inc. research and development expense for fiscal 2023 was $70.10M, a 93.69% increase from fiscal 2022.
- Structure Therapeutics Inc. research and development expense for fiscal 2022 was $36.19M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $100.06M 10-Q · filed 2026-08-06 | $166.56M 10-Q · filed 2026-08-06 | $235.25M derived: sum of 3 quarters · filed 2026-08-06 | $294.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $66.51M 10-Q · filed 2026-05-07 | $135.20M derived: sum of 2 quarters · filed 2026-05-07 | $194.19M derived: sum of 3 quarters · filed 2026-05-07 | $248.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $68.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $127.68M derived: sum of 2 quarters · filed 2026-02-26 | $182.39M derived: sum of 3 quarters · filed 2026-08-06 | $225.25M 10-K · filed 2026-02-26 |
| 2025-09-30 | $58.99M 10-Q · filed 2025-11-06 | $113.70M derived: sum of 2 quarters · filed 2026-08-06 | $156.57M 10-Q · filed 2025-11-06 | $190.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $54.71M 10-Q · filed 2026-08-06 | $97.58M 10-Q · filed 2026-08-06 | $131.06M derived: sum of 3 quarters · filed 2026-08-06 | $163.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $42.87M 10-Q · filed 2026-05-07 | $76.35M derived: sum of 2 quarters · filed 2026-05-07 | $108.95M derived: sum of 3 quarters · filed 2026-05-07 | $131.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $33.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $66.08M derived: sum of 2 quarters · filed 2026-02-26 | $88.14M derived: sum of 3 quarters · filed 2026-02-26 | $108.81M 10-K · filed 2026-02-26 |
| 2024-09-30 | $32.60M 10-Q · filed 2025-11-06 | $54.65M derived: sum of 2 quarters · filed 2025-11-06 | $75.33M 10-Q · filed 2025-11-06 | $95.37M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $22.05M 10-Q · filed 2025-08-06 | $42.73M 10-Q · filed 2025-08-06 | $62.77M derived: sum of 3 quarters · filed 2026-02-26 | $80.29M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $20.68M 10-Q · filed 2025-05-08 | $40.72M derived: sum of 2 quarters · filed 2026-02-26 | $58.24M derived: sum of 3 quarters · filed 2026-02-26 | $77.65M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $20.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $37.56M derived: sum of 2 quarters · filed 2026-02-26 | $56.97M derived: sum of 3 quarters · filed 2026-02-26 | $70.10M 10-K · filed 2026-02-26 |
| 2023-09-30 | $17.52M 10-Q · filed 2024-11-13 | $36.93M derived: sum of 2 quarters · filed 2024-11-13 | $50.06M 10-Q · filed 2024-11-13 | $58.42M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $19.41M 10-Q · filed 2024-08-08 | $32.55M 10-Q · filed 2024-08-08 | $40.91M derived: sum of 3 quarters · filed 2024-08-08 | $50.07M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $13.13M 10-Q · filed 2024-05-09 | $21.50M derived: sum of 2 quarters · filed 2024-05-09 | $30.66M derived: sum of 3 quarters · filed 2024-05-09 | $40.84M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $8.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $17.52M derived: sum of 2 quarters · filed 2024-03-08 | $27.70M derived: sum of 3 quarters · filed 2024-03-08 | $36.19M 10-K · filed 2024-03-08 |
| 2022-09-30 | $9.16M 10-Q · filed 2023-11-17 | $19.34M derived: sum of 2 quarters · filed 2023-11-17 | $27.83M 10-Q · filed 2023-11-17 | |
| 2022-06-30 | $10.18M 10-Q/A · filed 2023-11-17 | $18.67M 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | $8.49M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |